Olfactive Biosolutions

Olfactive Biosolutions, established in 2023, is a biotechnology firm focused on developing food-based therapeutics to address chronic diseases. The company was co-founded by Nils Lommerin, who serves as CEO, and Chris Hanson, the Chief Technology Officer. Lommerin, the former president and CEO of Del Monte Foods, brings extensive experience from the food and beverage and consumer packaged goods industries. Hanson founded Aromyx, a company that pioneered the digitization of taste and smell, and possesses a deep understanding of chemosensory receptors.

The company operates in the biotechnology and wellness markets, targeting both food and beverage manufacturers and direct consumers. Its business model involves a dual revenue stream: selling its patented formulations as ingredients to CPG companies and offering them as direct-to-consumer (DTC) supplements. This approach allows the company to tap into the large markets for weight management, blood sugar regulation, and hypertension.

Olfactive Biosolutions' core technology is the TruePath™ Receptor Platform, which utilizes artificial intelligence and engineered biosensor cells to analyze how food molecules interact with olfactory, taste, and ectopic receptors throughout the body. Ectopic receptors, which are the same as taste and smell receptors but located outside the nose and tongue, are involved in regulating metabolic processes. By identifying specific food molecules—listed as Generally Recognized as Safe (GRAS) by the FDA—that activate these receptors, the company creates formulations that can induce physiological benefits similar to pharmaceuticals but with minimal side effects.

The company's flagship product line is Pivit™, which includes formulations designed to manage weight, regulate blood sugar, and lower blood pressure. The Pivit weight loss product, for example, is an oral supplement that stimulates the natural secretion of multiple hunger-regulating hormones (GLP-1, PYY, GIP, and glucagon). This is designed to increase satiety, reduce appetite, and regulate blood sugar, offering a non-prescription, injection-free alternative to popular weight-loss drugs. The company has secured several patents for these compositions and plans to launch its DTC supplements in September 2025.

Keywords: ectopic receptors, food-based therapeutics, chemosensory receptors, GLP-1 agonist, Pivit, weight management supplement, blood sugar regulation, natural ingredients, biotechnology, food as medicine, consumer packaged goods ingredients, metabolic health, olfaction technology, biosensor cells, Nils Lommerin, Chris Hanson, Aromyx, direct-to-consumer supplements, food molecule formulation, chronic disease treatment